Clinical Trials on Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms in Czechia

Total 39 results

Angelini Pharma Česká republika s.r.o.
National Institute of Mental Health (NIMH); Institut biostatistiky a analýz... and other collaborators

Terminated

First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)

Adult Patients | Major Depressive Disorder Co-Occurrent With Anxiety | Newly Diagnosed Depression

Czechia
Charles University, Czech Republic

Recruiting

Pulse Width 0.15ms vs 0.30ms in Electroconvulsive Therapy (PWECT015)

Bipolar Depression | Major Depressive Disorder

Czechia
Sanofi

Completed

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder (CALYPSO)

Depressive Disorder | Major Depression

France, Poland, Romania, Russian Federation, Bulgaria, Serbia, Slovakia, Czech Republic, Mexico, Argentina, Croatia, Finland, South Africa
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Eli Lilly and Company

Completed

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Major Depressive Disorder (MDD)

United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
Affectis Pharmaceuticals AG
FGK Clinical Research GmbH

Completed

Cimicoxib for the Treatment of Major Depression (SECIM)

Major Depression

Austria, Czech Republic, Germany
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Hungary, India
Sanofi

Completed

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Depressive Disorder

United States, France, Russian Federation, Sweden, Turkey, Czech Republic, Mexico, Croatia
Neurocrine Biosciences

Completed

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) (SAVITRI)

Major Depressive Disorder

United States, Czechia, Bulgaria, Poland, Slovakia, Sweden
National Institute of Mental Health, Czech Republic

Completed

Ecologically Valid Virtual Tasks vs Paper-pencil Methods in Cognitive Rehabilitation in Patients With Schizophrenia and Depression

Depression | Schizophrenia | Cognitive Impairment

Czechia
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
H. Lundbeck A/S

Completed

Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression (VIVRE)

Major Depressive Disorder

Spain, Czechia, Slovakia, Estonia, Sweden, Argentina, Belgium, Bulgaria, Latvia, Mexico, Russian Federation, Ukraine
AbbVie

Completed

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Canada, Czechia, Finland, Poland, Puerto Rico, Serbia, Slovakia
Intra-Cellular Therapies, Inc.

Enrolling by invitation

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Germany, Hungary, Poland, Finland, India, Korea, Republic of, Sweden
Aziende Chimiche Riunite Angelini Francesco S.p.A

Completed

Trazodone Once a Day in Major Depression Disorder

Major Depressive Disorder

Austria, Czech Republic, Italy, Romania, Slovakia, Spain
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
H. Lundbeck A/S

Completed

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Major Depressive Disorder

Ukraine, Lithuania, France, Austria, Russian Federation, Australia, Belgium, Canada, Czech Republic, Finland, India, Korea, Republic of, Malaysia, Norway, Philippines, Serbia, Sweden
AstraZeneca
Targacept Inc.

Completed

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

Sweden, Czech Republic, Poland, Germany, Estonia, Latvia, Lithuania, Finland, France, Hungary
AstraZeneca

Completed

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder (ONYX)

Major Depressive Disorder

Sweden, Czech Republic, France, Germany, Poland, Romania, Finland, Norway, Belgium, Canada, Australia, South Africa
University of Regensburg
University Hospital Ostrava; Brno University Hospital; University Hospital, Aachen

Recruiting

rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia (RADOVAN)

Schizophrenia | Negative Symptoms With Primary Psychotic Disorder

Czechia, Germany
Takeda
H. Lundbeck A/S

Completed

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Major Depressive Disorder

France, Ukraine, Germany, Malaysia, South Africa, Korea, Republic of, Russian Federation, Czech Republic, Lithuania, United Kingdom, Latvia, Australia, Netherlands, Poland, Taiwan
Janssen-Cilag Ltd.

Active, not recruiting

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (ESCAPE-LTE)

Depressive Disorder, Major

Taiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
Sanofi

Completed

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Major Depressive Disorders

France, Netherlands, Bulgaria, Estonia, Serbia, Czech Republic, Croatia, Montenegro
Janssen Research & Development, LLC

Completed

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

Depressive Disorder, Major

United States, Taiwan, Czechia, Spain, Mexico, South Africa, Colombia, Russian Federation, Brazil, Bulgaria, Sweden
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

Depressive Disorder, Major

Belgium, Germany, France, Slovakia, Czech Republic, Finland
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

Depressive Disorder, Major

United States, Korea, Republic of, Taiwan, Slovakia, Spain, Bulgaria, Poland, Belgium, Argentina, Czechia, Hungary, South Africa, Sweden, Italy, France, Australia, China, Brazil, Portugal
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Migraine | Major Depressive Disorder

United States, Czechia, Finland, Israel, Italy, Russian Federation, Spain, Ukraine, France, Germany, Greece, Poland, United Kingdom
Janssen Research & Development, LLC

Completed

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (Aspire II)

Depressive Disorder, Major

United States, Belgium, Canada, Poland, France, Spain, Brazil, Lithuania, Czechia, Austria, Argentina, Turkey
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Slovakia, Brazil, Poland, Argentina, Bulgaria, Czechia, South Africa, Canada, United Kingdom, France
Janssen Research & Development, LLC

Completed

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1)

Depressive Disorder, Treatment-Resistant

United States, France, Poland, Belgium, Germany, Spain, Mexico, Turkey, Canada, Brazil, Estonia, Hungary, Slovakia, Sweden, Czechia
Solvay Pharmaceuticals

Terminated

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

United States, Czech Republic, Estonia, Israel, Poland
Prague Psychiatric Center

Unknown

A RCT Study in Schizophrenia Relapse Prevention

Relapse Schizophrenia

Czech Republic
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Janssen-Cilag International NV

Completed

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (PROSIPAL)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Poland, Bulgaria, Romania, Russian Federation, South Africa, Greece, Israel, Korea, Republic of, Belgium, Estonia, Turkey, Czech Republic, Austria, Hungary, Lithuania, Slovakia and more
Mundipharma Research GmbH & Co KG

Completed

A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain

Parkinson's Disease With Severe Pain

United Kingdom, Spain, Germany, Hungary, Czech Republic, Poland, Romania

Clinical Trials on Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations